1. Home
  2. PHAR vs PCRX Comparison

PHAR vs PCRX Comparison

Compare PHAR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$13.00

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$22.66

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
PCRX
Founded
1988
2006
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2020
2010

Fundamental Metrics

Financial Performance
Metric
PHAR
PCRX
Price
$13.00
$22.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$38.33
$30.25
AVG Volume (30 Days)
9.6K
497.0K
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.44
EPS
N/A
0.07
Revenue
N/A
$541,533,000.00
Revenue This Year
$10.04
$6.78
Revenue Next Year
$2.51
$8.54
P/E Ratio
$3,041.22
$333.79
Revenue Growth
N/A
26.04
52 Week Low
$8.69
$18.80
52 Week High
$21.34
$27.64

Technical Indicators

Market Signals
Indicator
PHAR
PCRX
Relative Strength Index (RSI) 27.63 39.46
Support Level $11.02 $22.13
Resistance Level $17.79 $24.20
Average True Range (ATR) 0.38 1.27
MACD -0.52 -0.30
Stochastic Oscillator 15.00 4.28

Price Performance

Historical Comparison
PHAR
PCRX

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: